Rheumatology Association of Nevada

Two Woodfield Lake
1100 E. Woodfield Road
Suite 350
Schaumburg, IL 60173

(847) 517-7225
(847) 517-7229
info@rheumatologynevada.org

Privacy Policy

SIGN UP FOR OUR MAILING LIST

Managed by
WJ Weiser & Associates, Inc.

Advocacy

SB 265 Passes Nevada Senate

SB 265, (Revises provisions relating to prescription drugs) has passed the Senate on May 19 and the Assembly on May 25. A major piece of pharmaceutical transparency legislation passed out of the Senate with bipartisan support Friday morning after weeks of behind-the-scenes discussions between lawmakers, pharmaceutical companies and others involved in the drug price-setting process.

The bill, sponsored by Democratic Sen. Yvanna Cancela, seeks to impose what could be the most robust mandates on pharmaceutical manufacturer transparency in the nation, requiring companies that manufacturer diabetes drugs disclose the list price of the drug, costs associated with manufacturing it and profits received, among other metrics.